Bath Salts (Synthetic Cathinones) and Ketamine Therapy | Tovani Health
Bath Salts (Synthetic Cathinones) (also: Flakka, Cloud Nine, MDPV, Mephedrone) — Synthetic stimulant (DEA Schedule I; recreational use illegal)
Verdict at Tovani Health
Severe sympathomimetic + serotonergic toxicity even alone; do not combine with ketamine.
'Bath salts' is a generic term for synthetic cathinones — designer drugs like MDPV, mephedrone, alpha-PVP ('flakka'), and methylone. They are DEA Schedule I controlled substances. Pharmacologically, they combine massive monoamine release (serotonin, norepinephrine, dopamine) with reuptake inhibition — similar mechanism family to MDMA and methamphetamine but typically more cardiovascular and more unpredictable. Documented effects include hypertensive crisis, tachyarrhythmias, hyperthermia, rhabdomyolysis, seizures, and psychotic episodes — often at doses people didn't intend (product purity varies wildly). Stacking with ketamine's pressor effect compounds the cardiovascular risk. Recent use disqualifies any ketamine session.
If you take Bath Salts regularly, at-home ketamine therapy isn't currently a fit — see below for why and what would need to change. This page covers the brief pharmacologic context and what we do at intake.
How Bath Salts interacts with ketamine
Synthetic cathinones inhibit monoamine reuptake and release serotonin, norepinephrine, and dopamine. MDPV is primarily dopaminergic; mephedrone is more serotonergic. All produce sympathomimetic and hyperthermic effects. The variability between batches and the contamination risk make the dose-effect curve unpredictable.
What we do at intake
Honest disclosure matters. We require at least 2-4 weeks of abstinence before starting KAP. Active stimulant use disorder warrants treatment-program coordination rather than at-home KAP.
Bottom line
'Bath salts' is a generic term for synthetic cathinones — designer drugs like MDPV, mephedrone, alpha-PVP ('flakka'), and methylone. They are DEA Schedule I controlled substances. Pharmacologically, they combine massive monoamine release (serotonin, norepinephrine, dopamine) with reuptake inhibition — similar mechanism family to MDMA and methamphetamine but typically more cardiovascular and more unpredictable. Documented effects include hypertensive crisis, tachyarrhythmias, hyperthermia, rhabdomyolysis, seizures, and psychotic episodes — often at doses people didn't intend (product purity varies wildly). Stacking with ketamine's pressor effect compounds the cardiovascular risk. Recent use disqualifies any ketamine session.
What would change this answer
We don’t prescribe at-home ketamine in this scenario today, but the situation can change. Talk to your prescribing physician about whether the underlying clinical picture (medication change, dose taper, indication shift, or stabilization milestone) might make you eligible later. We’re happy to revisit if your circumstances change.
For immediate mental health support, the 988 Suicide & Crisis Lifeline is available 24/7 (call or text 988).
Sources
The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.
- Neurotoxicology of Synthetic Cathinone Analogs. Angoa-Pérez M, Anneken JH, Kuhn DM. Current Topics in Behavioral Neurosciences. 2017. PMID: 27753008
- Cocaine-like discriminative stimulus effects of alpha-pyrrolidinovalerophenone, methcathinone and their 3,4-methylenedioxy analogs. Smith DA, Negus SS, Poklis JL. Addiction Biology. 2017. PMID: 27060605
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 22, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.